Skip to main content

REGULACION DE LA FUNCION DE BARRERA INTESTINAL POR CORTICOIDES, CALPROTECTINA, Y EL INTERCAMBIADOR SODIO-HIDROGENO NHE3

BFU2014-57736-P

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Insulin crystals grown in short-peptide supramolecular hydrogels show enhanced thermal stability and slower release profile

  • Contreras-Montoya, Rafael
  • Arredondo Amador, María
  • Escolano Casado, Guillermo
  • Mañas Torres, Maria C.
  • González, Mercedes
  • Conejero Muriel, Mayte
  • Bhatia, Vaibhav
  • Díaz Mochón, Juan José
  • Martínez Augustin, Olga
  • Sánchez de Medina, Fermín
  • Lopez-Lopez, Modesto T.
  • Conejero-Lara, Francisco
  • Gavira Gallardo, J. A.
  • Álvarez de Cienfuegos, Luis
[EN] Protein therapeutics have a major role in medicine in that they are used to treat diverse pathologies. Their three-dimensional structures not only offer higher specificity and lower toxicity than small organic compounds but also make them less stable, limiting their in vivo half-life. Protein analogues obtained by recombinant DNA technology or by chemical modification and/or the use of drug delivery vehicles has been adopted to improve or modulate the in vivo pharmacological activity of proteins. Nevertheless, strategies to improve the shelf-life of protein pharmaceuticals have been less explored, which has challenged the preservation of their activity. Herein, we present a methodology that simultaneously increases the stability of proteins and modulates the release profile, and implement it with human insulin as a proof of concept. Two novel thermally stable insulin composite crystal formulations intended for the therapeutic treatment of diabetes are reported. These composite crystals have been obtained by crystallizing insulin in agarose and fluorenylmethoxycarbonyl-dialanine (Fmoc-AA) hydrogels. This process affords composite crystals, in which hydrogel fibers are occluded. The insulin in both crystalline formulations remains unaltered at 50 °C for 7 days. Differential scanning calorimetry, high-performance liquid chromatography, mass spectrometry, and in vivo studies have shown that insulin does not degrade after the heat treatment. The nature of the hydrogel modifies the physicochemical properties of the crystals. Crystals grown in Fmoc-AA hydrogel are more stable and have a slower dissolution rate than crystals grown in agarose. This methodology paves the way for the development of more stable protein pharmaceuticals overcoming some of the existing limitations., The research leading to these results has received funding from the “la Caixa” Banking Foundation CaixaImpulse program, EIT-Health PocPlus program, and the Ministry of Economy and Competitiveness of Spain, acknowledged through the following projects: BIO2016-74875-P, BFU2014-57736-P, AGL2014-58883-R, SAF2017-88457-R, AGL2017-85270-R, and FIS2017-85954-R co-funded by Fondo Europeo de Desarrollo Regional, ERDF, European Union, and FEDER/Junta de Andalucía-Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Spain) projects P18-FR-3533, P12-FQM-2721, P12-FQM-790, CTS235, and CTS164. M.A.-A. and M.C.M.-T. were supported by fellowships from the Ministry of Education. CIBERehd is funded by Instituto de Salud Carlos III., Peer reviewed